# reload+after+2024-01-22 03:43:43.086893
address1§Modi’in Technology Park
address2§2 HaMa’ayan Street
city§Hevel Modi'in
zip§7177871
country§Israel
phone§972 8 642 9100
fax§972 8 642 9101
website§https://www.biolinerx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.
fullTimeEmployees§49
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA', 'age': 63, 'title': 'Chief Executive Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 635000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Mali  Zeevi CPA, CPA', 'age': 47, 'title': 'Chief Financial Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 380000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ella  Sorani', 'age': 55, 'title': 'Chief Development Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 457000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Holly W. May M.B.A.', 'age': 61, 'title': 'President of BioLineRx USA', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 328000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John  Lacey', 'title': 'Head of Corporate Communications & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Adam  Janoff Esq.', 'title': 'General Counsel & Head of Compliance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tsipi  Keren-Lehrer B.Sc., L.L.B.', 'title': 'Head of BD & Strategic Advisor', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Raziel  Fried', 'title': 'Treasurer & Budgetary Control Director', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.054
currency§USD
dateShortInterest§1702598400
forwardEps§-0.01
pegRatio§0.06
exchange§NCM
quoteType§EQUITY
shortName§BioLineRx Ltd.
longName§BioLineRx Ltd.
firstTradeDateEpochUtc§1311773400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§e62a36f1-05bb-3c53-9aee-d33adfbdf394
gmtOffSetMilliseconds§-18000000
targetHighPrice§21.0
targetLowPrice§7.6
targetMeanPrice§14.3
targetMedianPrice§14.3
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§1.785
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
